Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 35, p.5797-801 (2008)


Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, Child, Disease-Free Survival, Histocompatibility Testing, HLA Antigens, Humans, Leukemia, Myeloid, Acute, Proportional Hazards Models, RECURRENCE, Remission Induction, Risk Assessment, Survival Analysis, Time Factors, Treatment Outcome


There is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) for the treatment of pediatric patients with newly diagnosed acute myeloid leukemia (AML). Some oncologists have argued that BMT should be offered to most patients in first complete remission (CR). Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease. We performed this study to determine how disease risk influences the efficacy of BMT.